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gm/cm3 sd: 42.5, p = 0.01), but not with cortical density at the
14% site (1080.6 gm/cm3 sd: 52.3 vs 1069.8 gm/cm3 sd: 52.4,
p = 0.08) and 38% site (1150.3 gm/cm3 sd: 30.6 vs 1148.2
gm/cm3 sd: 33.8, p = 0.60). Tibia polar strength strain index
was also increased significantly at the 14% site (1739.05 sd:
445.1 vs 1607.41 sd: 410.47, p=0.007) and 38% site (1872.57
sd: 4790.34 vs 1716.34 sd: 428.934, p=0.002).
Tibio-femoral osteophytosis was associated with a significant
increase in total and trabecular BMD at the 4% site but not in
cortical BMD at 14% and 38% sites (see table). Joint space
narrowing displayed a weaker association with trabecular bone
density and and no significant association with cortical bone
density. Multivariate analyses of PQCT values adjusted to BMI,
gender and age were performed and did not significantly alter
the results
Conclusions: Radiographic osteoarthritis is associated with an
increase in volumetric BMD assessed by PQCT. However, this
increase is confined predominantly to trabecular bone rather
than cortical bone. This association is driven predominently by
the presence of osteophytes rather than joint space narrowing.
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Purpose: It is unclear whether changes in measures of self-
reported pain used in clinical trials, such as the visual analogue
scale (VAS), are clinically relevant to patients. The Patient Ac-
ceptable Symptom State (PASS) was developed to assess a
meaningful clinical response from the patient’s perspective. A
set of symptom threshold scores has been proposed to indicate
when patients consider themselves to be well and satisfied with
treatment. The treatment of osteoarthritis (OA) pain and dis-
ease activity with lumiracoxib, celecoxib and placebo in terms of
sustained acceptable symptom state using the PASS criteria is
assessed here.
Methods: Data from two 13-week, international, multicentre,
randomized, double-blind, double-dummy, placebo-controlled,
parallel-group studies were pooled and analysed. The studies
included patients aged ≥18 years with symptomatic knee OA
(American College of Rheumatology criteria), OA pain intensity
in the target knee (≥40 mm on a 100 mm VAS), and requiring
analgesic therapy for ≥3 months. Patients were randomized to
receive lumiracoxib 100 mg once daily (od), lumiracoxib 100 mg
od following an initial dose of lumiracoxib 200 mg od for the first
2 weeks (100 mg od + initial dose), celecoxib 200 mg od or
placebo for 13 weeks. OA pain intensity in the target knee, pa-
tient’s global assessment of disease activity, both 100 mm VAS,
and the WOMAC™ LK 3.1 Function (difficulty in performing daily
activities) sub-scale score were assessed. The PASS thresholds
were defined as ≤32.3 mm (VAS) for OA pain intensity, ≤32.0 mm
(VAS) for the patient’s global assessment of disease activity and
P325 – Table 1. K-M estimates of the % of patients achieving treatment satisfaction, according to PASS criteria#
Lumiracoxib100 mg od Lumiracoxib100 mg od + initial dose Celecoxib200 mg od Placebo
(n=811) (n=805) (n=813) (n=806)
OA Pain intensity (K-M %) 32.88** 33.87*** 33.06** 26.61
Patient’s global assessment (K-M %) 31.55*** 30.04*** 29.71*** 21.99
WOMACTM Function score (K-M %) 31.86*** 31.70*** 29.61*** 22.08
#Sustained until the end of the 13-week treatment phase. **p<0.01; ***p<0.001 versus placebo, Wilcoxon test
≤21.08 (converted from VAS to Likert scale) for the WOMAC™
Function score. The time taken to achieve and maintain an ac-
ceptable symptom state (PASS) for all subsequent consecutive
visits until the end of the study was determined for each variable.
Kaplan-Meier (K-M) probabilities of achieving a PASS sustained
until the end of the 13-week treatment phase were estimated. K-
M probabilities were calculated up to the penultimate study visit
(scheduled at 8 weeks [Day 73]) because achievement of PASS
after this visit would be insufficient to demonstrate a sustained
effect. Pairwise treatment comparisons of K-M estimates were
evaluated using Wilcoxon tests.
Results: For OA pain intensity, patient’s global assessment of
disease activity, and the WOMAC™ Function sub-scale score, the
probability of achieving an acceptable symptom state, according
to the PASS criteria, sustained until the end of the 13-week
treatment phase, was significantly greater for lumiracoxib 100 mg
od (with or without initial dose) than for placebo. This was true
also for celecoxib 200 mg od. There was no significant difference
between celecoxib 200 mg od and either of the lumiracoxib
regimens for the achievement of sustained acceptable symptom
state for the three PASS criteria.
Conclusions: In terms of PASS criteria for OA pain intensity,
patients’ global assessment of disease activity, and WOMAC
function, treatment satisfaction sustained until the end of 13
weeks of treatment in OA patients is significantly more likely with
100 mg od lumiracoxib than with placebo. Lumiracoxib 100 mg
od and celecoxib 200 mg od showed similar efficacy, that was
considered clinically relevant to the patients, as assessed by
PASS.
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Purpose: During knee osteoarthritis (OA) several processes
influence the progression. Histology suggests that cartilage le-
sions cause focal thinning and denudation whereas generalized
OA causes gradual, global thinning. In this longitudinal study, we
investigated which of these processes that is most prominent
and evaluated two alternative cartilage thinning measures that
are focused towards global and focal thinning, respectively, for
their ability to monitor OA progression as defined by the Kellgren
& Lawrence score (KL).
Methods: A randomized population was selected with even
distribution among male and female with ages from 21 to 81
(mean 56) and BMI from 20 to 38 (mean 27). Both left and right
knees and both healthy and knees with varying degree of OA
were used giving a total of 249 knees in the study.
The KL score was determined from digital x-rays acquired in a
weight bearing position with the knees slightly flexed and the feet
in a fixed rotation.
MR scans were acquired using a sagittal Turbo 3D T1 sequence
on a 0.18T Esaote C-Span scanner with near-isotropic voxels and
slice thickness of 0.8mm. X-rays and MR scans were acquired
at baseline and after 21 months.
